Soligenix Files 8-K with Bylaw Amendments and Exhibits
Ticker: SNGX · Form: 8-K · Filed: Mar 28, 2025 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financials
TL;DR
Soligenix filed an 8-K on 3/25/25 for bylaw changes and financial docs.
AI Summary
Soligenix, Inc. filed an 8-K on March 25, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits. The company, previously known as Dor Biopharma Inc. and Immunotherapeutics Inc., is incorporated in Delaware and has its fiscal year end on December 31.
Why It Matters
This filing indicates corporate housekeeping and the submission of financial information, which is crucial for investors to assess the company's current standing and compliance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial events or strategic shifts that would inherently increase risk.
Key Players & Entities
- SOLIGENIX, INC. (company) — Filer
- DOR BIOPHARMA INC (company) — Former Company Name
- IMMUNOTHERAPEUTICS INC (company) — Former Company Name
- March 25, 2025 (date) — Date of Earliest Event Reported
FAQ
What specific amendments were made to Soligenix, Inc.'s articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What financial statements and exhibits are being filed with this 8-K?
The filing states that financial statements and exhibits are being filed, but the specific list or content of these documents is not detailed in the provided excerpt.
When was Soligenix, Inc. previously known as Dor Biopharma Inc. and Immunotherapeutics Inc.?
The company was formerly known as Dor Biopharma Inc. with a date of name change not specified in the excerpt, and formerly known as Immunotherapeutics Inc. with a date of name change of 19920703.
What is the primary business of Soligenix, Inc. according to its SIC code?
Soligenix, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
Where is Soligenix, Inc. incorporated and what is its fiscal year end?
Soligenix, Inc. is incorporated in Delaware (DE) and its fiscal year ends on December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding SOLIGENIX, INC. (SNGX).